Huahai Pharmaceutical (600521.SH) issued an announcement stating that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (abbreviation “...
Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) announced that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (“Changxing Pharmaceutical”, stock code “835269”) is a listed company at the innovation level of the national SME share transfer system. Changxing Pharmaceutical disclosed the “2023 Annual Report of Changxing Pharmaceutical Co., Ltd.” on the National SME Share Transfer System on March 18, 2024.
During the reporting period, Changxing Pharmaceutical achieved operating income of 468 million yuan, a year-on-year increase of 45.82%; net profit attributable to shareholders of the parent company was 669.17,400 yuan, up 10.74% year on year; net profit attributable to shareholders of the parent company after deducting non-recurring profit and loss was 62.9761 million yuan, an increase of 13.19% year on year; basic earnings per share were 1.12 yuan/share.